Pirfenidone has been shown to reduce lung cancer growth in murine models by down-regulating the TGFβ pathway leading to an increase in NK and T cells infiltration [145] and giving a rationale for combination with atezolizumab in patients with lung cancer (NCT04467723). This evidence concerns the gene TGFB1 and lung cancer.